drugset
drugset / Trial / NCT04877769

Bronchopulmonary PK of AT-527 (R07496998)

NCT04877769 ↗

Phase 1 Completed 24 enrolled Atea Pharmaceuticals, Inc. Hoffmann-La Roche · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of AT-527 (R07496998)

Timeline

Start
2021-04-25
Primary completion
2021-08-31
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — —

Indications

No indication recorded.